State Street Corp Reduces Holdings in Hookipa Pharma Inc (NASDAQ:HOOK)

State Street Corp reduced its position in Hookipa Pharma Inc (NASDAQ:HOOK) by 90.0% in the 3rd quarter, Holdings Channel reports. The firm owned 16,967 shares of the company’s stock after selling 152,723 shares during the period. State Street Corp’s holdings in Hookipa Pharma were worth $73,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in HOOK. Acadian Asset Management LLC increased its position in Hookipa Pharma by 12.3% during the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after buying an additional 108,844 shares during the period. Renaissance Technologies LLC grew its position in shares of Hookipa Pharma by 38.4% during the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after acquiring an additional 83,800 shares during the last quarter. Finally, Ikarian Capital LLC acquired a new position in shares of Hookipa Pharma in the 3rd quarter valued at $228,000. 63.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HOOK. JMP Securities decreased their price target on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a research note on Thursday, November 21st. Royal Bank of Canada downgraded shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $48.00 to $2.00 in a research note on Friday, December 20th.

Hookipa Pharma Price Performance

Shares of NASDAQ HOOK opened at $1.86 on Friday. The stock has a fifty day moving average price of $2.67 and a 200 day moving average price of $4.28. Hookipa Pharma Inc has a 1-year low of $1.75 and a 1-year high of $10.50. The company has a market cap of $22.42 million, a PE ratio of -0.50 and a beta of 0.71.

Hookipa Pharma Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.